Spire Wealth Management Boosts IDEXX Laboratories Stock Position

Institutional investor significantly increases stake in veterinary diagnostics company

Mar. 31, 2026 at 9:22am

An extreme close-up of various metal and glass laboratory instruments and equipment, conveying the advanced technology and scientific expertise of IDEXX Laboratories without using any text or identifiable branding.Spire Wealth Management's significant investment in IDEXX Laboratories highlights the firm's confidence in the veterinary diagnostics company's growth potential.Westbrook Today

Spire Wealth Management grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1,096.0% in the 4th quarter, according to the company's most recent SEC filing. The institutional investor now owns 2,117 shares of the company's stock, valued at $1.43 million.

Why it matters

IDEXX Laboratories is a leading provider of diagnostic products and services for the animal health, water testing, and food safety markets. This significant increase in Spire Wealth Management's position suggests the firm sees strong growth potential for IDEXX's business.

The details

Spire Wealth Management's holdings in IDEXX Laboratories were worth $1.43 million at the end of the most recent reporting period, up from just $123,000 in the prior quarter. The firm added 1,940 shares to its position, a 1,096% increase. Other hedge funds, including Eastern Bank, LVW Advisors, and Global X Japan, also boosted their stakes in IDEXX during the fourth quarter.

  • Spire Wealth Management increased its IDEXX Laboratories position in the 4th quarter of 2025.

The players

Spire Wealth Management

An institutional investor that significantly increased its stake in IDEXX Laboratories.

IDEXX Laboratories, Inc.

A global developer, manufacturer, and provider of diagnostic products and services primarily for the animal health, water testing, and food safety markets.

Got photos? Submit your photos here. ›

The takeaway

Spire Wealth Management's substantial increase in its IDEXX Laboratories position suggests the firm sees strong growth potential for the veterinary diagnostics company, which could signal broader confidence in the animal health market.